A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Fludarabine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 07 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Oct 2007 New trial record.